Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC34H30F4N6O2 |
InChIKeyCPGQPOXVSPWIPH-UHFFFAOYSA-N |
CAS Registry2848564-14-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS G12C mutation Solid Tumors | Preclinical | CN | 03 Nov 2023 |